hotspot -WSS

hotspot

author：leisure time 2025-08-26 23:44:23 - browse：859

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： AstraZeneca loses challenge to Medicare drug price negotiation

WSS

Popular nasal decongestant doesn't actually relieve congestion

FogPharma raises $145 million in rare Series E round

How to address the problem of discarded donor organs

Regeneron agrees to White House price limits on anti

New Covid vaccine is recommended for everyone 6 months or older

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

focus

hotspot

explore

Moonlake's readout produced a cash windfall. Risks remain

How to address the problem of discarded donor organs

As demand for Covid shots wanes, Moderna seeks its next success

Food makers tried to stack nutrition panel with preferred experts

Affirmative action in medical school literally saved lives

Why getting cancer drugs just got harder for rural patients

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Apple is now the first public company to be valued at $3 trillion

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

entertainment

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

In search for therapies for solid tumors, companies turn to claudin

How to fix the rural physician shortage in the U.S.

Walmart eyes Medicare Advantage provider ChenMed

Hospitals consider fixing cancer drug shortages on their own

Medical device lobby: We're tired of waiting on Medicare coverage

knowledge

leisure time

leisure time

entertainment